Insulet’s (PODD) Buy Rating Reiterated at Canaccord Genuity Group

Canaccord Genuity Group reiterated their buy rating on shares of Insulet (NASDAQ:PODD) in a report released on Tuesday morning, Benzinga reports. They currently have a $234.00 target price on the medical instruments supplier’s stock.

PODD has been the subject of several other reports. Jefferies Financial Group lifted their target price on Insulet from $255.00 to $260.00 and gave the company a buy rating in a research note on Friday, May 10th. Raymond James lowered their target price on Insulet from $218.00 to $213.00 and set an outperform rating for the company in a research note on Friday, May 10th. Barclays lowered their target price on Insulet from $213.00 to $200.00 and set an equal weight rating for the company in a research note on Monday, May 13th. Wolfe Research raised Insulet from a peer perform rating to an outperform rating and set a $200.00 target price for the company in a research note on Tuesday, May 7th. Finally, OTR Global reissued a mixed rating on shares of Insulet in a research note on Monday, June 10th. Four analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and an average target price of $239.18.

Insulet Trading Down 1.8 %

Shares of PODD opened at $190.88 on Tuesday. The stock has a fifty day moving average price of $193.12 and a two-hundred day moving average price of $184.80. The company has a debt-to-equity ratio of 1.72, a quick ratio of 2.75 and a current ratio of 3.74. Insulet has a 52-week low of $125.82 and a 52-week high of $283.07. The company has a market cap of $13.37 billion, a price-to-earnings ratio of 57.84, a PEG ratio of 3.50 and a beta of 1.16.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, May 9th. The medical instruments supplier reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.34. Insulet had a return on equity of 34.06% and a net margin of 13.14%. The firm had revenue of $441.70 million during the quarter, compared to the consensus estimate of $424.05 million. During the same quarter in the previous year, the company posted $0.23 EPS. The business’s revenue for the quarter was up 23.3% compared to the same quarter last year. Analysts predict that Insulet will post 3.11 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, SVP Mark N. Field sold 1,500 shares of the business’s stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $199.96, for a total value of $299,940.00. Following the sale, the senior vice president now directly owns 12,875 shares in the company, valued at $2,574,485. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, SVP Mark N. Field sold 1,500 shares of the business’s stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $199.96, for a total value of $299,940.00. Following the sale, the senior vice president now directly owns 12,875 shares in the company, valued at $2,574,485. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Timothy J. Scannell sold 7,000 shares of the business’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $190.51, for a total value of $1,333,570.00. Following the completion of the sale, the director now owns 35,586 shares in the company, valued at $6,779,488.86. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 13,931 shares of company stock worth $2,636,286. Corporate insiders own 0.47% of the company’s stock.

Institutional Trading of Insulet

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Consolidated Portfolio Review Corp raised its holdings in Insulet by 1.6% during the fourth quarter. Consolidated Portfolio Review Corp now owns 3,713 shares of the medical instruments supplier’s stock worth $806,000 after acquiring an additional 57 shares in the last quarter. FourThought Financial Partners LLC increased its position in Insulet by 1.4% during the fourth quarter. FourThought Financial Partners LLC now owns 4,461 shares of the medical instruments supplier’s stock worth $968,000 after buying an additional 61 shares during the last quarter. Linden Thomas Advisory Services LLC increased its position in Insulet by 1.3% during the fourth quarter. Linden Thomas Advisory Services LLC now owns 5,817 shares of the medical instruments supplier’s stock worth $1,262,000 after buying an additional 73 shares during the last quarter. Lindbrook Capital LLC increased its position in Insulet by 64.1% during the fourth quarter. Lindbrook Capital LLC now owns 192 shares of the medical instruments supplier’s stock worth $42,000 after buying an additional 75 shares during the last quarter. Finally, Moody National Bank Trust Division increased its position in Insulet by 2.6% during the first quarter. Moody National Bank Trust Division now owns 3,439 shares of the medical instruments supplier’s stock worth $589,000 after buying an additional 87 shares during the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.